Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

Cancers

Volumn 6, Issue 3, 2014, Pages 1753-1768

  Martinetti, Antonia ^a   Miceli, Rosalba ^a   Sottotetti, Elisa ^a   Di Bartolomeo, Maria ^a   de Braud, Filippo ^a   Gevorgyan, Arpine ^a   Dotti, Katia Fiorella ^a   Bajetta, Emilio ^b   Campiglio, Manuela ^a   Bianchi, Francesca ^a   Bregni, Giacomo ^a   Pietrantonio, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b AO San Gerardo   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Biomarkers; CEA; Colorectal cancer; SDF 1; VEGF

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; IRINOTECAN; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1; TUMOR MARKER; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOASSAY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLEX ASSAY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TUMOR VOLUME;

EID: 84939147848     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6031753     Document Type: Article

References (39)

1. Kim, K.J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H.S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841–844.
2. Weis, S.M.; Cheresh, D.A. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat. Med. 2011, 17, 1359–1370.
3. Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozin, S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145–147.
4. Jain, R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307, 58–62.
5. Presta, L.G.; Chen, H.; O’Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57, 4593–4599.
6. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335–2342.
7. Kabbinavar, F.F.; Schulz, J.; McCleod, M.; Patel, T.; Hamm, J.T.; Hecht, J.R.; Mass, R.; Perrou, B.; Nelson, B.; Novotny, W.F. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J. Clin. Oncol. 2005, 23, 3697–3705.
8. Giantonio, B.J.; Catalano, P.J. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007, 25, 1539–1544.
9. Di Bartolomeo, M.; van Cutsem, E.; Michael, M.; Berry, S.; Rivera, F.; Kretzschmar, A.; Mazier, M.; Lutiger, B.; Cunningham, D. Feasibility of metastasectomy in patients treated with first-line bevacizumab for MCRC: Preliminary results from the first BEAT-study (first BEAT investigators). Ann. Oncol. 2006, 17, Abstract No. 373P.
10. Ribero, D.; Wang, H.; Donadon, M.; Zorzi, D.; Thomas, M.B.; Eng, C.; Chang, D.Z.; Curley, S.A.; Abdalla, E.K.; Ellis, L.M., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110, 2761–2767.
11. Jubb, A.M.; Harris, A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010, 11, 1172–1183.
12. Di Bartolomeo, M.; Bajetta, E.; Buzzoni, R.; Dotti, K.F; Mariani, L.; Filippelli, G.; Aitini, E.; Ciarlo, A.; Barone, C.; Cirillo, M., et al. Efficacy of three different bevacizumab-containing first-line regimens for metastatic colorectal cancer (MCRC): A randomized phase II study by Italian Trials in Medical Oncology (ITMO) Group. Tumori 2010, 10, Abstract No A1.
13. Machida, N.; Yoshino, T.; Boku, N.; Hironaka, S.; Onozawa, Y.; Fukutomi, A.; Yamazaki, K.; Yasui, H.; Taku, K.; Asaka, M. Impact of baseline sum of longest diameter in target lesion by RECIST on survival of patients with metastatic colorectal cancer. Jpn. J. Clin. Oncol. 2008, 38, 689–694.
14. Durrleman, S.; Simon, R. Flexible regression models with cubic splines. Stat. Med. 1989, 8, 551–561.
15. Akaike, H. Information theory and an extension of the Maximum Likelihood principle. In Proceedings of the 2nd International Symposium on Information Theory, Tsahkadsor, Armenia, 2–8 September 1971; Petrov, B.N., Csaki, F., Eds.; Akadèmiai Kiado: Budapest, Ungary, 1973; pp. 267–281.
16. The R Software for Statistical Computing. Available online: http://www.R-project.org (accessed on 19 August 2014)
17. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669–676.
18. Lee, J.C.; Chow, N.H.; Wang, S.T.; Huang, S.M. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer 2000, 36, 748–753.
19. Hyodo, I.; Doi, T.; Endo, H.; Hosokawa, Y.; Nishikawa, Y.; Tanimizu, M.; Jinno, K.; Kotani, Y. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur. J. Cancer 1998, 34, 2041–2045.
20. Jubb, A.M.; Hurwitz, H.I.; Bai, W.; Holmgren, E.B.; Tobin, P.; Guerrero, A.S.; Kabbinavar, F.; Holden, S.N.; Novotny, W.F.; Frantz, G.D., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. 2006, 24, 217–227.
21. Kopetz, S.; Hoff, P.M.; Morris, J.S.; Wolff, R.A.; Eng, C.; Glover, K.Y.; Adinin, R.; Overman, M.J.; Valero, V.; Wen, S., et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010, 28, 453–459.
22. Cristofanilli, M.; Charnsangavej, C.; Hortobagyi, G.N. Angiogenesis modulation in cancer research: Novel clinical approaches. Nat. Rev. Drug Discov. 2002, 1, 415–426.
23. Gordon, M.S.; Margolin, K.; Talpaz, M.; Sledge, G.W., Jr.; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001, 19, 843–850.
24. Lee, K.Y.; Peters, M.C.; Anderson, K.W.; Mooney, D.J. Controlled growth factor release from synthetic extracellular matrices. Nature 2000, 408, 998–1000.
25. Willett, C.G.; Duda, D.G.; di Tomaso, E.; Boucher, Y.; Ancukiewicz, M.; Sahani, D.V.; Lahdenranta, J.; Chung, D.C.; Fischman, A.J.; Lauwers, G.Y., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J. Clin. Oncol. 2009, 27, 3020–3026.
26. Loupakis, F.; Falcone, A.; Masi, G.; Fioravanti, A.; Kerbel, R.S.; del Tacca, M.; Bocci, G. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J. Clin. Oncol. 2007, 25, 1816–1818.
27. Loupakis, F.; Cremolini, C.; Fioravanti, A.; Orlandi, P.; Salvatore, L.; Masi, G.; di Desidero, T.; Canu, B.; Schirripa, M.; Frumento, P., et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br. J. Cancer 2011, 104, 1262–1269.
28. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E., McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50–56.
29. Zhu, A.X.; Sahani, D.V.; Duda, D.G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O.A.; Sindhwani, V.; Blaszkowsky, L.S.; Yoon, S.S.; Lahdenranta, J., et al. Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J. Clin. Oncol. 2009, 27, 3027–3035.
30. Siegel, A.B.; Cohen, E.I.; Ocean, A.; Lehrer, D.; Goldenberg, A.; Knox, J.J.; Chen, H.; Clark-Garvey, S.; Weinberg, A.; Mandeli, J., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 2008, 26, 2992–2998.
31. Freyer, G.; Rougier, P.; Bugat, R.; Droz, J.P.; Marty, M.; Bleiberg, H.; Mignard, D.; Awad, L.; Herait, P.; Culine, S., et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. Br. J. Cancer 2000, 83, 431–437.
32. Tournigand, C.; Andre, T.; Achille, E.; Ledo, G.; Flesh, M.; Mery-Mignard, D.; Quinaux, E.; Couteau, C.; Buyse, M.; Ganem, G., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol. 2004, 22, 229–237.
33. Locker, G.Y.; Hamilton, S.; Harris, J.; Jessup, J.M.; Kemeny, N.; Macdonald, J.S.; Somerfield, M.R.; Hayes, D.F.; Bast, R.C., Jr.; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24, 5313–5327.
34. Petrioli, R.; Licchetta, A.; Roviello, G.; Pascucci, A.; Francini, E.; Bargagli, G.; Conca, R.; Miano, S.T.; Marzocca, G.; Francini, G., et al. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. Cancer Invest. 2012, 30, 65–71.
35. Strimpakos, A.S.; Cunningham, D.; Mikropoulos, C.; Petkar, I.; Barbachano, Y.; Chau, I. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann. Oncol. 2010, 21, 1013–1019.
36. Sorbye, H.; Dahl, O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. J. Clin. Oncol. 2003, 21, 4466–4467.
37. De Andrade, D.P.; Lima, J.P.; Lima, A.D.; Sasse, A.D.; dos Santos, L.V. Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: Case report and review of literature. Anticancer Drugs 2011, 22, S15–S17.
38. Prager, G.W.L.; Braemswig, K.H.; Martel, A.; Unseld, M.; Heinze, G.; Brodowicz, T.; Scheithauer, W.; Kornek, G.; Zielinski, C.C. Baseline CEA serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci. 2014, doi:10.1111/cas.12451.
39. Jürgensmeier, J.M.; Schmoll, H.J.; Robertson, J.D.; Brooks, L.; Taboada, M.; Morgan, S.R.; Wilson, D.; Hoff, P.M. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br. J. Cancer 2013, 108, 1316–1323.